Outcomes of whole-body photobiomodulation on pain, quality of life, leisure physical activity, pain catastrophizing, kinesiophobia, and self-efficacy: a prospective randomized triple-blinded clinical trial with 6 months of follow-up
Metadatos
Mostrar el registro completo del ítemEditorial
Frontiers Media
Materia
Fibromyalgia Chronic pain Quality of life
Fecha
2024-01-31Referencia bibliográfica
Navarro-Ledesma S, Carroll JD, González-Muñoz A and Burton P (2024) Outcomes of whole-body photobiomodulation on pain, quality of life, leisure physical activity, pain catastrophizing, kinesiophobia, and self-efficacy: a prospective randomized triple-blinded clinical trial with 6 months of follow-up. Front. Neurosci. 18:1264821. doi: 10.3389/fnins.2024.1264821
Resumen
Background: The management of fibromyalgia (FM) symptoms on a global
scale remains a complex endeavor. This study endeavors to assess the impact
of whole-body photobiomodulation (PBM) compared to placebo PBM on
pain, functionality, and psychological symptoms in individuals afflicted with
fibromyalgia.
Objectives: The primary objectives of this research were to conduct a
comparative analysis of the effects of whole-body photobiomodulation (PBM)
and placebo PBM on pain, functionality, and psychological symptoms in patients
suffering from fibromyalgia (FM).
Methods: A total of 42 subjects were recruited from a private care practice
for participation in this triple-blinded, placebo-controlled, randomized clinical
trial. Participants underwent 12 treatment sessions, and assessments were
conducted at various intervals, including baseline (T0), midway through the
12-session treatment (T1), at the completion of the 12 sessions (T2), and followups
at 2 weeks (T3), 3 months (T4), and 6 months (T5).
Results: Statistical analysis revealed significant reductions in pain at T2, T3, and
T5. Additionally, quality of life exhibited marked improvements after sessions at
T1, T2, T3, T4, and T5. Leisure activity also demonstrated statistically significant
improvements at T2, T3, T4, and T5. Furthermore, kinesiophobia showed
significant differences between groups immediately after treatment at T2, T3,
T4, and T5. Self-efficacy, when compared between groups, demonstrated
significant differences at T3, T4, and T5 (two weeks after treatment). Lastly, pain
catastrophizing exhibited significant differences only at T5.
Conclusion: The findings of this study indicate that whole-body PBM treatment
for 4 weeks resulted in significant pain reduction and improved quality of life
in individuals suffering from FM. Furthermore, kinesiophobia and self-efficacy
demonstrated improvements in both short-term and long-term assessments, while pain catastrophizing showed improvement at the 6-month follow-up. Consequently, whole-body PBM emerges as a promising multifactorial treatment option for FM patients, though further studies are required to validate and strengthen these results.